A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma

por Qin, Shukui, Chan, Stephen Lam, Sukeepaisarnjaroen, Wattana, Han, Guohong, Choo, Su Pin, Sriuranpong, Virote, Pan, Hongming, Yau, Thomas, Guo, Yabing, Chen, Minshan, Ren, Zhenggang, Xu, Jianming, Yen, Chia-Jui, Lin, Zhong-Zhe, Manenti, Luigi, Gu, Yi, Sun, Yongjian, Tiedt, Ralph, Hao, Lu, Song, Wenjie, Tanwandee, Tawesak
Publicado 2019